News

TMCnet10h
ImCheck's Announces EMA Orphan Drug Designation for ICT01 as Treatment for Acute Myeloid Leukemia
Following the FDA ODD, European designation underscores ICT01’s potential as a novel immunotherapy approach in AML ...
Pharmabiz15h
US FDA grants orphan drug designation to ImCheck’s ICT01 for treatment of acute myeloid leukaemia
Marseille, France Monday, July 21, 2025, 12:00 Hrs [IST] ...
Targeted Oncology3d
Optimizing AML Treatment: ICT01 Receives FDA Orphan Drug Designation
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...
The Manila Times3d
ImCheck’s ICT01 Receives FDA Orphan Drug Designation for Treatment of Acute Myeloid Leukemia
ImCheck’s ICT01 Receives FDA Orphan Drug Designation Clinical data showing unprecedented remission rates in newly diagnosed ...
The Manila Times3d
Buxton, Elevar, and Audiense Unite Under a New Brand: Audiense
Fort Worth, TX, July 18, 2025 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE ...
Targeted Oncology16d
Advancements in Essential Thrombocythemia: Targeting External Proteins
Aaron T. Gerds, MD, discusses the unmet needs in the treatment of essential thrombocythemia, as well as novel methods for approaching disease treatment.